Displaying publications 61 - 80 of 6257 in total

Abstract:
Sort:
  1. Goh KL, Quek KF, Yeo GT, Hilmi IN, Lee CK, Hasnida N, et al.
    Aliment Pharmacol Ther, 2005 Nov 1;22(9):859-64.
    PMID: 16225496
    Colorectal cancer is one of the most common forms of gastrointestinal cancer in the world today. In the Asia-Pacific area, it is the fastest emerging gastrointestinal cancer.
    Matched MeSH terms: Cecal Neoplasms/ethnology; Cecal Neoplasms/epidemiology; Cecal Neoplasms/therapy; Colonic Neoplasms/ethnology; Colonic Neoplasms/epidemiology; Colonic Neoplasms/therapy; Neoplasms, Multiple Primary/ethnology; Neoplasms, Multiple Primary/epidemiology; Neoplasms, Multiple Primary/therapy; Rectal Neoplasms/ethnology; Rectal Neoplasms/epidemiology; Rectal Neoplasms/therapy; Sigmoid Neoplasms/ethnology; Sigmoid Neoplasms/epidemiology; Sigmoid Neoplasms/therapy; Colorectal Neoplasms/ethnology; Colorectal Neoplasms/epidemiology*; Colorectal Neoplasms/therapy
  2. Sinniah D, Chee CP, Pathmanathan R, Nuruddin R
    Med. Pediatr. Oncol., 1988;16(1):57-61.
    PMID: 3340064
    Matched MeSH terms: Brain Neoplasms/therapy; Cerebellar Neoplasms/therapy; Testicular Neoplasms/complications
  3. Ahluwalia HS, Duguid JB
    Br. J. Cancer, 1966 Mar;20(1):12-5.
    PMID: 5949191
    Matched MeSH terms: Mouth Neoplasms/epidemiology; Nasopharyngeal Neoplasms/epidemiology*; Neoplasms/epidemiology*
  4. Subramanyam C, Lal M
    Med J Malaya, 1970 Jun;24(4):306-7.
    PMID: 4248354
    Matched MeSH terms: Nasopharyngeal Neoplasms/pathology*; Nose Neoplasms/pathology*; Uterine Neoplasms/pathology
  5. Kutty MK, Balasegaram M
    J R Coll Surg Edinb, 1972 Mar;17(2):102-7.
    PMID: 5021743
    Matched MeSH terms: Liver Neoplasms/epidemiology; Lung Neoplasms/epidemiology; Neoplasms/epidemiology*
  6. Win TT, Aye SN, Abdul Hamad NS, Tuan Sharif SE
    Indian J Cancer, 2021 1 7;58(2):262-266.
    PMID: 33402586 DOI: 10.4103/ijc.IJC_528_19
    The primary retroperitoneal serous adenocarcinoma (PRSAC) is a rare malignant tumor of the retroperitoneum. It shares the same pathological and biological behavior with ovarian serous carcinoma. Most of the cases develop as peritoneal adenocarcinoma and rarely occur in the retroperitoneum. It is reported as serous surface papillary carcinoma of the peritoneum and extraovarian peritoneal serous papillary carcinoma. We present a case of PRSAC in a 60-year-old woman. Only 11 cases of PRSAC have been reported from 1983 to 2019. Histopathological features with immunohistochemical expressions are important to diagnose PRSAC. The outcome and survival mainly depend on the possibility of surgical resection. Molecular genetics of PRSAC should also be studied in relation with its ovarian counterpart.
    Matched MeSH terms: Ovarian Neoplasms/pathology*; Ovarian Neoplasms/surgery; Retroperitoneal Neoplasms/pathology*; Retroperitoneal Neoplasms/surgery
  7. Rohilla S, Singh M, Priya S, Almalki WH, Haniffa SM, Subramaniyan V, et al.
    PMID: 36734949 DOI: 10.1615/JEnvironPatholToxicolOncol.2022042088
    Melatonin is a serotonin-derived pineal gland hormone with many biological functions like regulating the sleep-wake cycle, circadian rhythm, menstrual cycle, aging, immunity, and antioxidants. Melatonin synthesis and release are more pronounced during the night, whereas exposure to light decreases it. Evidence is mounting in favor of the therapeutic effects of melatonin in cancer prevention, treatment and delayed onset in various cancer subtypes. Melatonin exerts its anticancer effect through modification of its receptors such as melatonin 1 (MT1), melatonin 2 (MT2), and inhibition of cancer cell proliferation, epigenetic alterations (DNA methylation/demethylation, histone acetylation/deacetylation), metastasis, angiogenesis, altered cellular energetics, and immune evasion. Melatonin performs a significant function in immune modulation and enhances innate and cellular immunity. In addition, melatonin has a remarkable impact on epigenetic modulation of gene expression and alters the transcription of genes. As an adjuvant to cancer therapies, it acts by decreasing the side effects and boosting the therapeutic effects of chemotherapy. Since current treatments produce drug-induced unwanted toxicities and side effects, they require alternate therapies. A recent review article attempts to summarize the mechanistic perspective of melatonin in different cancer subtypes like skin cancer, breast cancer, hepatic cancer, renal cell cancer, non-small cell lung cancer (NSCLC), colon oral, neck, and head cancer. The various studies described in this review will give a firm basis for the future evolution of anticancer drugs.
    Matched MeSH terms: Breast Neoplasms*; Kidney Neoplasms*; Lung Neoplasms*
  8. Loong HH, Shimizu T, Prawira A, Tan AC, Tran B, Day D, et al.
    ESMO Open, 2023 Aug;8(4):101586.
    PMID: 37356359 DOI: 10.1016/j.esmoop.2023.101586
    INTRODUCTION: Next-generation sequencing (NGS) diagnostics have shown clinical utility in predicting survival benefits in patients with certain cancer types who are undergoing targeted drug therapies. Currently, there are no guidelines or recommendations for the use of NGS in patients with metastatic cancer from an Asian perspective. In this article, we present the Asia-Pacific Oncology Drug Development Consortium (APODDC) recommendations for the clinical use of NGS in metastatic cancers.

    METHODS: The APODDC set up a group of experts in the field of clinical cancer genomics to (i) understand the current NGS landscape for metastatic cancers in the Asia-Pacific (APAC) region; (ii) discuss key challenges in the adoption of NGS testing in clinical practice; and (iii) adapt/modify the European Society for Medical Oncology guidelines for local use. Nine cancer types [breast cancer (BC), gastric cancer (GC), nasopharyngeal cancer (NPC), ovarian cancer (OC), prostate cancer, lung cancer, and colorectal cancer (CRC) as well as cholangiocarcinoma and hepatocellular carcinoma (HCC)] were identified, and the applicability of NGS was evaluated in daily practice and/or clinical research. Asian ethnicity, accessibility of NGS testing, reimbursement, and socioeconomic and local practice characteristics were taken into consideration.

    RESULTS: The APODDC recommends NGS testing in metastatic non-small-cell lung cancer (NSCLC). Routine NGS testing is not recommended in metastatic BC, GC, and NPC as well as cholangiocarcinoma and HCC. The group suggested that patients with epithelial OC may be offered germline and/or somatic genetic testing for BReast CAncer gene 1 (BRCA1), BRCA2, and other OC susceptibility genes. Access to poly (ADP-ribose) polymerase inhibitors is required for NGS to be of clinical utility in prostate cancer. Allele-specific PCR or a small-panel multiplex-gene NGS was suggested to identify key alterations in CRC.

    CONCLUSION: This document offers practical guidance on the clinical utility of NGS in specific cancer indications from an Asian perspective.

    Matched MeSH terms: Liver Neoplasms*; Nasopharyngeal Neoplasms*; Prostatic Neoplasms*
  9. Hasanpourghadi M, Looi CY, Pandurangan AK, Sethi G, Wong WF, Mustafa MR
    Curr Drug Targets, 2017;18(9):1086-1094.
    PMID: 27033190 DOI: 10.2174/1389450117666160401124842
    Phytometabolites are functional elements derived from plants and most of them exhibit therapeutic characteristics such as anti-cancer, anti-inflammatory and anti-oxidant effects. Phytometabolites exert their anti-cancer effect by targeting multiple signaling pathways. One of the remarkable phenomena targeted by phytometabolites is the Warburg effect. The Warburg effect describes the observation that cancer cells exhibit an increased rate of glycolysis and aberrant redox activity compared to normal cells. This phenomenon promotes further cancer development and progression. Recent observations revealed that some phytometabolites could target metabolic-related enzymes (e.g. Hexokinase, Pyruvate kinase M2, HIF-1) in cancer cells, with little or no harm to normal cells. Since hyper-proliferation of cancer cells is fueled by higher cellular metabolism, phytometabolites targeting these metabolic pathways can create synergistic crosstalk with induced apoptotic pathways and sensitize cancer cells to chemotherapeutic agents. In this review, we discuss phytometabolites that target the Warburg effect and the underlying molecular mechanism that leads to tumor growth suppression.
    Matched MeSH terms: Neoplasms/metabolism*; Neoplasms/pathology
  10. Rosenblatt E, Barton M, Mackillop W, Fidarova E, Cordero L, Yarney J, et al.
    Radiother Oncol, 2015 Jul;116(1):35-7.
    PMID: 26164776 DOI: 10.1016/j.radonc.2015.06.012
    Optimal radiotherapy utilisation rate (RTU) is the proportion of all cancer cases that should receive radiotherapy. Optimal RTU was estimated for 9 Middle Income Countries as part of a larger IAEA project to better understand RTU and stage distribution.
    Matched MeSH terms: Neoplasms/pathology; Neoplasms/radiotherapy*
  11. Lim GCC
    Med J Malaysia, 2003 Dec;58(5):632-5.
    PMID: 15190645
    Matched MeSH terms: Neoplasms/epidemiology*; Neoplasms/therapy
  12. Ahmad MF, Abu MA, Abdul Karim AK
    J Adolesc Young Adult Oncol, 2020 12;9(6):693-694.
    PMID: 33090942 DOI: 10.1089/jayao.2020.0105
    Matched MeSH terms: Neoplasms/complications*; Neoplasms/pathology
  13. Lie-Injo LE, Caldwell J, Ganesan S, Ganesan J
    Cancer, 1976 Jul;38(1):341-5.
    PMID: 59626 DOI: 10.1002/1097-0142%28197607%2938%3A1<341%3A%3AAID-C
    The level of serum alpha-fetoprotein (AFP) was estimated by radioimmunoassay in 153 normal healthy Malysians of different ethnic groups. The mean level was 7.5 In1/ml (SD 2.28InU/ml). Among 330 patients with malignant tumors, 11 had increased levels of AFP. The only patient who had hepatoma had a very high level of serum AFP. High levels were also found in three of four patients with dysgerminoma of the ovary, in the only two patients with carcinoma of the testis, and in one patient with secondary carcinoma of the humerus of unknown origin. Lower, but significantly increased levels were observed in one patient (of 48) with breast carcinoma, one patient (of 8) with basal cell carcinoma of the nose, one patient (0f 27) with carcinoma of the lung, and one patient (of 59) with nasopharynegeal carcinoma.
    Matched MeSH terms: Breast Neoplasms/blood; Liver Neoplasms/blood; Neoplasms/blood*; Nose Neoplasms/blood; Ovarian Neoplasms/blood; Testicular Neoplasms/blood
  14. Fadli, A.R., David, O., Azmi, M.N., Zailani, M.H.
    MyJurnal
    Distant metastasis is a common sequelae of stage III colorectal adenocarcinoma. Liver and lungs are the
    most common sites for distant metastases, but, metastases to extremities are very rare. We report a case of rectosigmoid adenocarcinoma, which metastasizes to left first metacarpal bone, which is the first occurrence in our experience. The investigations and management of the patient are discussed.
    Matched MeSH terms: Rectal Neoplasms; Sigmoid Neoplasms; Neoplasms, Second Primary
  15. Huat LH
    Med J Malaysia, 1979 Sep;34(1):32-7.
    PMID: 542148
    Matched MeSH terms: Breast Neoplasms/epidemiology; Uterine Cervical Neoplasms/epidemiology; Liver Neoplasms/epidemiology; Lung Neoplasms/epidemiology; Neoplasms/epidemiology*; Stomach Neoplasms/epidemiology
  16. Ramanathan K, Lakshimi S
    Med J Malaysia, 1974 Mar;28(3):143-8.
    PMID: 4278210
    Matched MeSH terms: Gingival Neoplasms/epidemiology; Jaw Neoplasms/epidemiology*; Lip Neoplasms/epidemiology; Mouth Neoplasms/epidemiology*; Palatal Neoplasms/epidemiology; Tongue Neoplasms/epidemiology
  17. Syadwa AS, Anita ZB
    Med J Malaysia, 2018 08;73(4):190-196.
    PMID: 30121680 MyJurnal
    AIM: Symptomatic relief following palliative radiotherapy for advanced cancers may take a few weeks up to a few months to achieve. Thus, accurate prognostication is important to avoid harm to these patients with limited lifespan. We conducted a retrospective cohort study to determine the median survival and 30-day mortality (30-DM) and factors associated with these parameters in our centre.

    METHODS: Data from 585 eligible patients who received palliative radiotherapy between January 2012 and December 2014 were analysed. Median overall survival was calculated from the commencement of first fraction of the last course of radiotherapy to date of death or when censored. 30-DM was calculated as the proportion of patients who died within 30 days from treatment start date. Kaplan-Meier survival analysis was used to estimate survival. Chi-square test and logistic regression was used to assess the impact of potential prognostic factors on median survival and 30-DM.

    RESULTS: The most common diagnoses were lung and breast cancers and most common irradiated sites were bone and brain. Median survival and 30-DM were 97 days and 22.7% respectively. Primary cancer, age, treatment course, performance status, systemic treatment post radiotherapy and intended radiotherapy treatment completed had an impact on median survival whereas mainly the latter three factors had an impact on 30-DM.

    CONCLUSION: Median survival and factors affecting both survival and 30-DM in our study are comparable to others. However, a 30-DM rate of 22.7% is significantly higher compared to the literature. We need to better select patients who will benefit from palliative radiotherapy in our centre.

    Matched MeSH terms: Breast Neoplasms/diagnosis; Breast Neoplasms/mortality; Breast Neoplasms/radiotherapy; Lung Neoplasms/diagnosis; Lung Neoplasms/mortality; Lung Neoplasms/radiotherapy; Neoplasms/diagnosis; Neoplasms/mortality; Neoplasms/radiotherapy*
  18. Sharudin SN, Tan SW, Mohamad NF, Vasudevan SK, Khairan H, Mun YC, et al.
    Orbit, 2018 Jun;37(3):196-200.
    PMID: 29058523 DOI: 10.1080/01676830.2017.1383474
    A 25-year-old Chinese woman presented with recurrent painless swelling over the left medial canthus region for 3 months and intranasal mass for an indeterminate duration. Initial incision biopsy of the mass was reported as nodular fasciitis but the lesion recurred 3 weeks later. Intraoperative findings during repeat biopsy showed a mass extending from the deep dermal tissue into the anterior orbit and polyp-like nasal mass. Histopathology findings were that of dermatofibrosarcoma protuberans (DFSP). The mass recurred 4 months later without orbital or intranasal recurrence. Wide excision biopsy under frozen section guidance was attempted however; clear surgical margins could not be achieved despite extensive resection. She was subsequently referred for adjuvant radiotherapy. We report an exceptionally rare case of local recurrence of DFSP in an unusual anatomic location. This case was surgically challenging in achieving negative margins, and thus neoadjuvant therapy may improve overall outcome to prevent local relapse.
    Matched MeSH terms: Facial Neoplasms/pathology*; Facial Neoplasms/radiotherapy; Nose Neoplasms/pathology*; Nose Neoplasms/radiotherapy; Orbital Neoplasms/pathology*; Orbital Neoplasms/radiotherapy; Skin Neoplasms/pathology*; Skin Neoplasms/radiotherapy
  19. Erejuwa OO, Sulaiman SA, Ab Wahab MS
    Oxid Med Cell Longev, 2013;2013:931251.
    PMID: 24369491 DOI: 10.1155/2013/931251
    Cancer cells generate reactive oxygen species (ROS) resulting from mitochondrial dysfunction, stimulation of oncogenes, abnormal metabolism, and aggravated inflammatory activities. Available evidence also suggests that cancer cells depend on intrinsic ROS level for proliferation and survival. Both physiological and pathophysiological roles have been ascribed to ROS which cause lipid peroxidation. In spite of their injurious effects, the ROS and the resulting lipid peroxidation products could be beneficial in cancer treatment. This review presents research findings suggesting that ROS and the resulting lipid peroxidation products could be utilized to inhibit cancer growth or induce cancer cell death. It also underscores the potential of lipid peroxidation products to potentiate the antitumor effect of other anticancer agents. The review also highlights evidence demonstrating other potential applications of lipid peroxidation products in cancer treatment. These include the prospect of lipid peroxidation products as a diagnostic tool to predict the chances of cancer recurrence, to monitor treatment progress or how well cancer patients respond to therapy. Further and detailed research is required on how best to successfully, effectively, and selectively target cancer cells in humans using lipid peroxidation products. This may prove to be an important strategy to complement current treatment regimens for cancer patients.
    Matched MeSH terms: Neoplasms/drug therapy*; Neoplasms/metabolism*; Neoplasms/pathology
  20. Badrisyah I, Saiful R, Rahmat H, Naik VR, Tan YC
    Med J Malaysia, 2012 Dec;67(6):613-5.
    PMID: 23770956 MyJurnal
    Metastasis of an atrial myxoma to the brain is extremely rare. Thus far there are only 17 cases reported, including our present case. Most of the brain metastases manifest only in 3 to 6 decades, after an average time frame of one to two years after surgical removal of parental tumour. We present a case of brain metastases of atrial myxoma in a teenager of the youngest age among all reported cases, unusually as early as 15 years old. The progress of the metastatic process had been insidious for three years after heart surgery, The imaging demonstrated a rather sizeable tumour by the time when the patient is symptomatic. The location of the metastatic tumour is anyhow superficial to the cortical surface, enabling complete surgical excision of the tumour easily achievable with favourable outcome.
    Matched MeSH terms: Brain Neoplasms/surgery; Heart Neoplasms*
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links